Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.38
22.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hansoh Pharmaceutical Group Company Ltd
Retained Earnings
Hansoh Pharmaceutical Group Company Ltd
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Retained Earnings
¥11.7B
|
CAGR 3-Years
36%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Retained Earnings
¥11.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
24%
|
CAGR 10-Years
26%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Retained Earnings
¥34.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Retained Earnings
¥20.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Retained Earnings
¥1.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Retained Earnings
-¥1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hansoh Pharmaceutical Group Company Ltd
Glance View
Hansoh Pharmaceutical Group Company Ltd., founded in 1995 and headquartered in Jiangsu, China, has rapidly evolved into one of the leading biopharmaceutical enterprises in the country. With a robust portfolio that spans biologics, small molecule drugs, and innovative therapies, Hansoh has carved a niche for itself by focusing on high-demand therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases. The company thrives on its commitment to research and development, partnering with academic institutions and international firms to drive innovation, which is pivotal in a competitive industry characterized by rapid technological advancements. Investors will find comfort in Hansoh's strong growth trajectory, marked by impressive revenue increases and a strategic intent to expand its footprint both domestically and globally. As the Chinese healthcare market continues to burgeon, driven by an aging population and evolving consumer demands, Hansoh Pharmaceutical is well-positioned to capitalize on these trends. Its recent listings on major global stock exchanges signal its ambition to attract international investors and strengthen its balance sheet for future endeavors. The company's strategic initiatives aim to diversify its product offerings and improve access to its innovative drugs, setting it apart from its competitors. With a management team that emphasizes prudent decision-making and value creation—echoing the principles of investment legends like Warren Buffett and Charlie Munger—Hansoh is not just a company; it is a growing story of success in the burgeoning pharmaceutical landscape that promises to deliver sustained value for its shareholders in the years to come.
See Also
What is Hansoh Pharmaceutical Group Company Ltd's Retained Earnings?
Retained Earnings
11.7B
CNY
Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's Retained Earnings amounts to 11.7B CNY.
What is Hansoh Pharmaceutical Group Company Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
61%
Over the last year, the Retained Earnings growth was 29%. The average annual Retained Earnings growth rates for Hansoh Pharmaceutical Group Company Ltd have been 36% over the past three years , 61% over the past five years .
You don't have any saved screeners yet
